BioArctic Is No Longer the Biotech You Think It Is

BioArctic's stock trades at a trailing P/E of 126 — the kind of multiple you see on a pre-revenue biotech betting on one trial. The problem is BioArctic isn't that company anymore.

It collects royalties on a drug that has been selling globally for over a year, is approved in 53 countries, and is forecast to grow 63% next year. BioArctic doesn't fund the development. It doesn't run the sales force. It just gets paid 9% on every dollar. And it has been licensing the same brain-delivery platform that made that drug possible to four additional pharma partners this year alone.

The company has been restructured from a speculative bet into a royalty engine with platform optionality attached. The multiple hasn't caught up to what the business now is.

The royalty machine

The core of BioArctic's income is Leqembi (lecanemab), the world's first disease-modifying treatment for early Alzheimer's disease. BioArctic discovered the antibody in 2005 and licensed it to Eisai for global development and commercialization. The deal terms are one-sided in BioArctic's favor: no development costs, regulatory milestone payments, and royalties on global sales.

The royalty stream is no longer theoretical. Leqembi generated roughly $177 million in global sales during the second quarter of 2026, up organically about 43% year-over-year. That quarter alone produced SEK 179 million in royalty income for BioArctic. Eisai has forecast full fiscal-year 2026 (April 2026 to March 2027) Leqembi revenue of JPY 143.5 billion — approximately SEK 8.4 billion — which would generate roughly SEK 880 million in royalty payments to BioArctic.

Compare that to 2025, when total company revenue was SEK 2 billion. The bulk of that came from a one-off milestone package triggered by earlier regulatory approvals. Without those milestone spikes, recurring royalty revenue is smaller but accelerating fast. The company went from posting a negative loss of SEK -8.8 million in Q4 2025 to an operating profit of SEK 33.2 million in the same quarter, and the full-year 2025 operating profit exceeded SEK 1.2 billion.

The subcutaneous formulation, branded Leqembi Iqlik, changes the commercial trajectory. It was approved by the FDA on July 13 and launched in the U.S. on August 24, 2026. Patients can now start and maintain treatment with an at-home autoinjector instead of weekly intravenous infusions. The LEADER Study data presented at the July 2026 Alzheimer's Association International Conference showed that 82.5% of patients remained stable or improved over an average of 17 months of treatment, and the subcutaneous formulation demonstrated efficacy and safety comparable to intravenous administration.

A drug for early Alzheimer's that patients can inject at home in a market with over 5 million patients in the U.S. alone — this is how royalty streams scale.

The platform gets the attention

Here's what the market is paying less attention to: BioArctic's proprietary BrainTransporter technology is becoming a licensing product.

BrainTransporter actively moves antibodies across the blood-brain barrier — the single biggest barrier to treating most neurological diseases. Before Leqembi, nobody had proven a reliable way to do it at scale. Now pharma companies are lining up to license it.

In the past 12 months, BioArctic has signed four major partnerships building on BrainTransporter:

• Bristol Myers Squibb (December 2024): Global license for BAN1503 and BAN2803, the first BrainTransporter license agreement, targeting pyroglutamate-modified amyloid-beta in Alzheimer's.
• Novartis (August 2025): Research collaboration to combine BrainTransporter with an undisclosed neurodegenerative target. Novartis will evaluate the resulting candidate and decide whether to take global development.
• Eli Lilly (June 2026): Collaboration to pair BrainTransporter with a Lilly drug candidate in neurodegeneration. Upfront payment of $30 million, with up to $770 million in milestone payments.
• Mesenkia Therapeutics (August 2026): Research collaboration targeting glioblastoma — the company's first move into oncology — combining BrainTransporter with Mesenkia's KITAIbodies platform.

This isn't a pipeline. It's a technology platform that generates cash upfront, creates milestone optionality, and doesn't require BioArctic to fund large-scale trials. The company generates the candidate; the partner evaluates and takes the risk. That's why BioArctic's cash position grew to SEK 2.19 billion by the end of 2025 and remained strong at SEK 2.03 billion through Q1 2026.

What the market hasn't priced in

The stock trades around SEK 330 per share, with a market capitalization of approximately SEK 29.3 billion, and a trailing P/E of 126. Analyst consensus targets average around SEK 310. AInvest's aggregate signal labels the stock as overweight.

The trailing multiple looks expensive. But BioArctic isn't the same company it was a year ago, and the P/E denominator doesn't reflect the accelerating royalty base.

Think of it this way: analysts project roughly SEK 3 billion in revenue for calendar 2026. At SEK 29 billion, the stock trades at approximately 9.7x forward revenue — not the multiple of a speculative biotech. If the SEK 880 million in annualized royalties becomes the new baseline and continues to grow, the multiple contracts faster than the headline P/E suggests.

The BrainTransporter deals add a second layer. The $30 million upfront from Lilly alone is roughly SEK 310 million — that's nearly half of last year's royalty income from a single deal. If even a fraction of those $770 million in milestones materializes, it changes the revenue picture meaningfully.

The bear case is real

The numbers only work if Leqembi keeps growing. There are reasons to doubt that trajectory.

European adoption is sluggish. The Swedish National Board of Health and Welfare recently declined to recommend Leqembi for the Swedish healthcare system. Denmark gave a similar negative recommendation. In the Nordics — BioArctic's home market and where it holds commercialization rights — patients have no access while patients in the U.S., Japan, and China get the drug. These are cost-effectiveness decisions, not clinical ones, but they matter for revenue.

The 9% royalty rate is fixed. BioArctic doesn't participate in pricing improvements or volume bonuses beyond the base percentage. Growth comes from Eisai's sales, not BioArctic's control.

Insider selling has been heavy. CEO Gunilla Osswald sold shares in August 2025, February 2026, and throughout the period. Board members including founder Lars Lannfelt sold roughly 3.1 million shares between August 2025 and December 2025, worth over SEK 700 million combined. This looks like profit-taking after a strong run — the stock rose from the mid-200 SEK range in early 2025 to over 360 by mid-2026 — but it also signals that the people closest to the company see limited upside from current levels, or they're simply diversifying after years of concentration.

What changes the story

The FDA approval of the subcutaneous initiation dose on July 13, 2026, was the latest structural catalyst. A home injectable for Alzheimer's opens a patient population that couldn't tolerate weekly infusions. If U.S. adoption accelerates post-launch, the royalty trajectory steepens.

Eisai's JPY 143.5 billion forecast for FY26 represents 63% growth. If the company hits or exceeds that — the subcutaneous rollout, EU expansion of four-week IV dosing, and Chinese market entry all point that way — BioArctic's royalty base crosses a new threshold.

The BrainTransporter pipeline will generate its next set of data points over the coming 12 to 24 months. Preclinical results from the Mesenkia collaboration, candidate generation for the Novartis and Lilly deals, and Phase 2a readouts for the Parkinson's program (exidavnemab) will determine whether the platform story deepens or stalls.

The company is not a fallen stock. It trades at a premium because the underlying business has real momentum. The question for investors is whether the momentum justifies the multiple, or whether the market has already bid this in. At roughly 10x forward revenue, with a SEK 2 billion cash position and a growing royalty base from a drug in 53 countries, the math is defensible — but not cheap. The edge, if there is one, comes from the subcutaneous launch accelerating faster than the base case assumes, or from BrainTransporter milestones arriving sooner than the consensus expects.